Philippines

Population 2018: 107 million

<table>
<thead>
<tr>
<th>Estimates of TB burden*, 2018</th>
<th>Number (thousands)</th>
<th>Rate (per 100 000 population)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total TB incidence</td>
<td>591 (332–924)</td>
<td>554 (311–866)</td>
</tr>
<tr>
<td>HIV-positive TB incidence</td>
<td>10 (4.1–19)</td>
<td>9.4 (3.8–17)</td>
</tr>
<tr>
<td>MDR/RR-TB incidence**</td>
<td>18 (7.7–32)</td>
<td>17 (7.3–30)</td>
</tr>
<tr>
<td>HIV-negative TB incidence</td>
<td>26 (22–30)</td>
<td>24 (20–28)</td>
</tr>
<tr>
<td>HIV-positive TB mortality</td>
<td>0.6 (0–4.2)</td>
<td>0.57 (0–4)</td>
</tr>
</tbody>
</table>

Estimated proportion of TB cases with MDR/RR-TB, 2018

- % tested with rapid diagnostics at time of diagnosis: 36%
- % with known HIV status: 27%
- % pulmonary: 98%
- % bacteriologically confirmed***: 36%
- % children aged 0–14 years: 12%
- % women: 30%
- % men: 58%

Total cases notified: 382,543

Universal health coverage and social protection

TB treatment coverage (notified/estimated incidence), 2018: 63% (40–110)
TB patients facing catastrophic total costs, 2017: 35% (33–37)
TB case fatality ratio (estimated mortality/estimated incidence), 2018: 5% (3–7)

Drug-resistant TB care, 2018

- % of bacteriologically confirmed TB cases tested for rifampicin resistance***
  - New cases: <1%
  - Previously treated cases: 24%

Laboratory-confirmed cases*

Patients started on treatment**

MDR/RR-TB: 7,276, XDR-TB: 52
MDR/RR-TB: 6,125, XDR-TB: 52
MDR/RR-TB cases tested for resistance to second-line drugs: 2,095

Treatment success rate and cohort size

New and relapse cases registered in 2017: 91% 315,923
Previously treated cases, excluding relapse, registered in 2017: 82% 9,486
HIV-positive TB cases registered in 2017: 83% 1,258
MDR/RR-TB cases started on second-line treatment in 2016: 58% 5,071
XDR-TB cases started on second-line treatment in 2016: 20% 10

TB preventative treatment, 2018

- % of HIV-positive people (newly enrolled in care) on preventive treatment: 52%
- % of children (aged < 5) household contacts of bacteriologically-confirmed TB cases on preventive treatment: 9.4% (8.7–10)

TB financing, 2019

National TB budget (US$ millions): 205
Funding source: 12% domestic, 25% international, 63% unfunded

*Ranges represent uncertainty intervals
** MDR is TB resistant to rifampicin and isoniazid; RR is TB resistant to rifampicin
*** Calculated for pulmonary cases only
Includes cases with unknown previous TB treatment history
** Includes patients diagnosed before 2018 and patients who were not laboratory-confirmed

Data are as reported to WHO. Estimates of TB and MDR-TB burden are produced by WHO in consultation with countries. Generated: 2019-12-21